Thus, it would be interesting to assess whether novel once-weekly subcutaneous long-acting amylin analogs (like cagrilintide) or novel co-formulations containing long-acting amylin analogs and long-acting GLP-1 RA (like CagriSema, which contains cagrilintide and semaglutide) [175] can exert a therapeutic role in patients with T1D, double diabetes and LADA. This evidence concerns the gene GCG and type 1 diabetes mellitus.